Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 12/20 | 0.42 |
| ▸ | CNR1 | P21554 | 6/20 | 0.37 |
| ▸ | PCK1 | P35558 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | GNRHR | P30968 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4924516 | 0.85 | CNR2 (0.43) | CNR2CNR1BRD4CREBBPGNRHR | |
| SCHEMBL4926913 | 0.82 | CNR2 (0.48) | CNR2CNR1PCK1 | |
| SCHEMBL4785209 | 0.80 | P2RX3 (0.42) | BRD4CREBBPL3MBTL1 | |
| SCHEMBL14113974 | 0.78 | BRD4 (0.51) | CNR2CNR1BRD4CREBBP | |
| SCHEMBL4784570 | 0.78 | CNR1 (0.37) | CNR2CNR1PCK1HTR2AHTR2C | |
| SCHEMBL14144734 | 0.75 | BRD4 (0.46) | CNR2CNR1BRD4CREBBP | |
| SCHEMBL4924719 | 0.75 | BRD4 (0.44) | CNR2BRD4CREBBPKMT2A | |
| SCHEMBL4929940 | 0.74 | BRD4 (0.66) | CNR2CNR1BRD4CREBBPHTR2A | |
| SCHEMBL4923915 | 0.73 | BRD4 (0.49) | CNR2CNR1BRD4CREBBP | |
| SCHEMBL4914588 | 0.73 | BRD4 (0.50) | CNR2CNR1BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008079316-A1 | TETRAHYDROQUINOLINONES, TETRAHYDRONAPHTHYRIDONES AND DERIVATIVES THEREOF | CARA THERAPEUTICS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079316-A1 | TETRAHYDROQUINOLINONES, TETRAHYDRONAPHTHYRIDONES AND DERIVATIVES THEREOF | CARA THERAPEUTICS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20080161340-A1 | Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof | CARA THERAPEUTICS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161340-A1 | Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof | CARA THERAPEUTICS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161340-A1 | Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof | CNR1, CNR2, TRPV1 | CNR2 2/4885CNR1 1/4885PCK1 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.